All In Biotech

Drug Trial Radar · NCT07023081

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant

A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHINESE ADULTS, CHILDREN, AND INFANTS

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Actual

Start

Jun 15, 2025

Primary completion

Jun 10, 2027

Study completion Jun 10, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 42 days, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years of age in China. This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China. This study is seeking healthy participants of 6 groups: * Group 1: Adults ≥18 to \<50 years of age * Group 2: Children ≥2 to \<6 years of age * Group 3: Children ≥12 months to \<2 years of age * Group 4: Infants ≥7 to \<12 months of age * Group 5: Infants ≥42 to ≤98 days of age * Group 6: Infants ≥42 to ≤98 days of age All participants in Group 1 to 5, in this study will receive 20vPnC as per the age-specific dosing schedules: * Group 1: participants will receive 1 dose of 20vPnC. * Group 2: participants will receive 1 dose of 20vPnC. * Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1. * Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to \<455 days of age and at least 56 days after Dose 2. * Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age. Participants in Group 6 will be randomized in a 1:1 ratio to received either 20vPnC or 13vPnC: \- Group 6: participants will receive 4 doses of 20vPnC or 13vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to \<455 days of age. The study will look at the experiences of people receiving the study vaccine. The study will also look at the immune response of some people receiving the study vaccine. This will help decide if the study vaccine is safe. The total duration of taking part in the study from each group is: * Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits. * Participants in Group 3 will take part for about 8 months, with 9 visits. * Participants in Group 4 will take part for about 12 months, with 8 visits. * Participants in Group 5 and 6 will take part for about 16 to 19 months, with 11 visits.

Conditions

  • Pneumococcal Disease

Interventions

  • 20vPnCBiological

    20vPnC vaccine

  • 13vPnCBiological

    13vPnC vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting prespecified local reactions within 7 days following each study interventionTime frame: Within 7 days of each study intervention
  2. Percentage of participants reporting prespecified systemic events within 7 days following each study interventionTime frame: Within 7 days of each study intervention
  3. Percentage of participants reporting adverse events (AEs) from the first study intervention through 1 month following the last study intervention administrationTime frame: 1 month after the last vaccination
  4. Percentage of participants reporting AEs from the first study intervention through 1 month following the third study intervention.Time frame: From the first study intervention to 1 month after the third study intervention
  5. Percentage of participants reporting AEs from the fourth study intervention to 1 month following the fourth study intervention.Time frame: From the fourth study intervention to 1 month after the fourth study intervention
  6. Percentage of participants reporting serious adverse events (SAEs) throughout the studyTime frame: From the first study intervention to 6 months after the last study intervention

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    Nanning, Guangxi, China

  • Wuming District Center for Disease Control and Prevention

    Chengxiang, Nanning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.